Literature DB >> 11440093

Effect of intravenous immunoglobulin on inhibiting peripheral blood lymphocyte apoptosis in acute Kawasaki disease.

Q J Yi1, C R Li, X Q Yang.   

Abstract

UNLABELLED: This study aimed to explore the therapeutic mechanism of intravenous immunoglobulin (IVIG) for Kawasaki disease (KD). Peripheral blood lymphocytes (PBLs) obtained from 26 children with KD and 20 age-matched healthy children were stimulated with anti-CD3 monoclonal antibody (mAb), and the percentage of apoptotic cells and DNA fragmentation were assayed at 0, 12, 24, 48 and 72 h in vitro. The patients were divided into two groups: one treated with aspirin combined with IVIG (n = 16) and one treated with aspirin alone (n = 10). PBLs were stimulated by phytohaemagglutinin to evaluate the lymphocyte proliferative response. Compared with normal controls, the apoptotic cell percentage and the DNA fragmentation were markedly decreased (p < 0.001) and delayed in PBLs from KD patients. After IVIG treatment, the decreased percentage of apoptotic cell and delayed DNA fragmentation were restored to the state of the normal controls, accompanied by a fast clinical remission compared with the aspirin-alone group. The lymphocyte proliferative response was also decreased 3-5 d after IVIG therapy (p < 0.001).
CONCLUSION: The results suggest that decreased PBL apoptosis may be involved in the pathogenesis of KD. The therapeutic mechanism of IVIG in KD may be partially due to the reversal of the inhibited lymphocyte apoptosis, and may have implications for other autoimmune diseases with inefficient lymphocyte apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11440093

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  6 in total

Review 1.  Update on the treatment of Kawasaki disease in childhood.

Authors:  Robert P Sundel
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

Review 2.  Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease.

Authors:  T Matsubara; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

3.  Common variants in CASP3 confer susceptibility to Kawasaki disease.

Authors:  Yoshihiro Onouchi; Kouichi Ozaki; Jane C Buns; Chisato Shimizu; Hiromichi Hamada; Takafumi Honda; Masaru Terai; Akihito Honda; Takashi Takeuchi; Shoichi Shibuta; Tomohiro Suenaga; Hiroyuki Suzuki; Kouji Higashi; Kumi Yasukawa; Yoichi Suzuki; Kumiko Sasago; Yasushi Kemmotsu; Shinichi Takatsuki; Tsutomu Saji; Tetsushi Yoshikawa; Toshiro Nagai; Kunihiro Hamamoto; Fumio Kishi; Kazunobu Ouchi; Yoshitake Sato; Jane W Newburger; Annette L Baker; Stanford T Shulman; Anne H Rowley; Mayumi Yashiro; Yoshikazu Nakamura; Keiko Wakui; Yoshimitsu Fukushima; Akihiro Fujino; Tatsuhiko Tsunoda; Tomisaku Kawasaki; Akira Hata; Yusuke Nakamura; Toshihiro Tanaka
Journal:  Hum Mol Genet       Date:  2010-04-27       Impact factor: 6.150

4.  Predicting factors for refractory kawasaki disease.

Authors:  Young-Sun Do; Ki-Won Kim; Jin-Kyong Chun; Byung Ho Cha; Mee Kyung Namgoong; Hae Yong Lee
Journal:  Korean Circ J       Date:  2010-05-27       Impact factor: 3.243

5.  Intravenous Immunoglobulin Therapy Restores the Quantity and Phenotype of Circulating Dendritic Cells and CD4+ T Cells in Children With Acute Kawasaki Disease.

Authors:  Nana Wang; Zhongyue Chen; Fan Zhang; Qianwen Zhang; Ling Sun; Haitao Lv; Bo Wang; Jie Shen; Xufang Zhou; Feiyan Chen; Binwei Zhang; Lijun Meng; Huiting Zhou; ZhenJiang Bai; Jie Huang
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

Review 6.  Understanding the pathogenesis of Kawasaki disease by network and pathway analysis.

Authors:  Yu-wen Lv; Jing Wang; Ling Sun; Jian-min Zhang; Lei Cao; Yue-yue Ding; Ye Chen; Ji-juan Dou; Jie Huang; Yi-fei Tang; Wen-tao Wu; Wei-rong Cui; Hai-tao Lv
Journal:  Comput Math Methods Med       Date:  2013-03-06       Impact factor: 2.238

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.